English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A 40-year-old HIV-positive female presented with an erythematous macular eruption involving the malar and periorbital area, the forehead and neck of six weeks of duration (A). She had initiated antiretroviral treatment with co-formulated tenofovir/lamivudine/efavirenz QD plus isoniazid preventive therapy (IPT) 18 weeks before with CD4 counts of 496 cells/¼u0003l (25%). Drug-induced subacute cutaneous lupus erythematous (DI-SCLE) secondary to isoniazid was clinically diagnosed and isoniazid was stopped. Antinuclear antibody (ANA), anti-SSA/Ro, anti-SSB/La, anti-Sm, anti-RNP and antihistone antibodies were negative. Complete blood count, eGFR and liver transaminases were normal. Three months after stopping isoniazid, the skin lesions resolved completely, supporting the diagnosis of isoniazid-induced SCLE (B). DI-SCLE with negative ANA has been described, but there are no reports in HIV-infected patients. With the current expanded provision of IPT to people living with HIV, it is important to be aware of this rare side effect of isoniazid despite the negativity of antibody assays.

the pan african medical journal

Isoniazid-induced subacute cutaneous lupus erythematosus in an HIV-positive woman: a rare side effect to be aware of with the current expansion of isoniazid preventive therapy